JP7302793B2 - Ｈｍｇｎ部分ペプチド及びこれを用いたがん療法 - Google Patents

Ｈｍｇｎ部分ペプチド及びこれを用いたがん療法 Download PDF

Info

Publication number
JP7302793B2
JP7302793B2 JP2020505099A JP2020505099A JP7302793B2 JP 7302793 B2 JP7302793 B2 JP 7302793B2 JP 2020505099 A JP2020505099 A JP 2020505099A JP 2020505099 A JP2020505099 A JP 2020505099A JP 7302793 B2 JP7302793 B2 JP 7302793B2
Authority
JP
Japan
Prior art keywords
amino acid
seq
peptide
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020505099A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019172358A5 (https=
JPWO2019172358A1 (ja
Inventor
綱治 松島
悟史 上羽
俊吾 弟子丸
昌佑 陳
祥司 横地
義郎 石渡
史朗 柴山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tokyo University of Science
Ono Pharmaceutical Co Ltd
University of Tokyo NUC
Original Assignee
Tokyo University of Science
Ono Pharmaceutical Co Ltd
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokyo University of Science, Ono Pharmaceutical Co Ltd, University of Tokyo NUC filed Critical Tokyo University of Science
Publication of JPWO2019172358A1 publication Critical patent/JPWO2019172358A1/ja
Publication of JPWO2019172358A5 publication Critical patent/JPWO2019172358A5/ja
Application granted granted Critical
Publication of JP7302793B2 publication Critical patent/JP7302793B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020505099A 2018-03-08 2019-03-07 Ｈｍｇｎ部分ペプチド及びこれを用いたがん療法 Active JP7302793B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2018041560 2018-03-08
JP2018041560 2018-03-08
JP2019014105 2019-01-30
JP2019014105 2019-01-30
PCT/JP2019/009015 WO2019172358A1 (ja) 2018-03-08 2019-03-07 Ｈｍｇｎ部分ペプチド及びこれを用いたがん療法

Publications (3)

Publication Number Publication Date
JPWO2019172358A1 JPWO2019172358A1 (ja) 2021-03-11
JPWO2019172358A5 JPWO2019172358A5 (https=) 2022-03-08
JP7302793B2 true JP7302793B2 (ja) 2023-07-04

Family

ID=67846101

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020505099A Active JP7302793B2 (ja) 2018-03-08 2019-03-07 Ｈｍｇｎ部分ペプチド及びこれを用いたがん療法

Country Status (5)

Country Link
US (2) US11572393B2 (https=)
EP (1) EP3763731A4 (https=)
JP (1) JP7302793B2 (https=)
TW (1) TW201938580A (https=)
WO (1) WO2019172358A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7302793B2 (ja) * 2018-03-08 2023-07-04 国立大学法人 東京大学 Ｈｍｇｎ部分ペプチド及びこれを用いたがん療法
EP4215214A4 (en) * 2020-09-16 2024-07-03 Osaka University THERAPEUTIC AGENT AGAINST CANCER, IMMUNOSTIMULANT AND SCREENING METHOD FOR ANTI-CANCER SUBSTANCE
CN114921443B (zh) * 2022-05-05 2023-07-07 重庆医科大学 肺炎链球菌肽链内切酶o在制备抗肿瘤药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011031477A2 (en) 2009-08-25 2011-03-17 Esperance Pharmaceuticals, Inc. Nucleolin-binding peptides, nucleolin-binding lytic peptides, fusion constructs and methods of making and using same
WO2015125652A1 (ja) 2014-02-21 2015-08-27 Ｉｄａｃセラノスティクス株式会社 固形がんの治療剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544767B2 (en) 2002-04-05 2009-06-09 Burnham Institute For Medical Research HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
US7714139B2 (en) * 2003-03-27 2010-05-11 Lankenau Institute For Medcial Research IDO inhibitors and methods of use
US8227417B2 (en) 2008-07-25 2012-07-24 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants
PT2374883T (pt) 2008-12-26 2016-10-20 Kyowa Hakko Kirin Co Ltd Anticorpo anti-cd4
WO2018047917A1 (ja) * 2016-09-09 2018-03-15 国立大学法人 東京大学 Ｈｍｇタンパク質と抗ｃｄ４抗体又は免疫チェックポイント制御剤との組み合わせによる相乗的抗腫瘍効果
JP7302793B2 (ja) * 2018-03-08 2023-07-04 国立大学法人 東京大学 Ｈｍｇｎ部分ペプチド及びこれを用いたがん療法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011031477A2 (en) 2009-08-25 2011-03-17 Esperance Pharmaceuticals, Inc. Nucleolin-binding peptides, nucleolin-binding lytic peptides, fusion constructs and methods of making and using same
WO2015125652A1 (ja) 2014-02-21 2015-08-27 Ｉｄａｃセラノスティクス株式会社 固形がんの治療剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cancer Res.，2014年，Vol.74 No.21，pp.5989-5998
Immunotherapy，2015年，Vol.7 No.11，pp.1129-1131
Proc. Natl. Acad. Sci. USA，2002年，Vol.99 No.11，pp.7444-7449

Also Published As

Publication number Publication date
EP3763731A4 (en) 2021-11-17
EP3763731A1 (en) 2021-01-13
US20230220022A1 (en) 2023-07-13
US20200407408A1 (en) 2020-12-31
WO2019172358A1 (ja) 2019-09-12
TW201938580A (zh) 2019-10-01
JPWO2019172358A1 (ja) 2021-03-11
US11919932B2 (en) 2024-03-05
US11572393B2 (en) 2023-02-07

Similar Documents

Publication Publication Date Title
KR102340832B1 (ko) 항 pd-1 항체 및 그의 용도
JP6952028B2 (ja) Ｐｄ−１抗体およびその使用
JP2024125370A (ja) クローディン１８．２結合部分およびその利用
US11919932B2 (en) HMGN partial peptide and cancer therapy using the same
JP7274426B2 (ja) 抗ｇｉｔｒアゴニスト抗体での癌の処置
JP2018521008A (ja) 腫瘍形成を処置するための治療用組成物および治療方法
JP7754506B2 (ja) ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用
RS54846B1 (sr) Novo anti-dr5 antitelo
TW201622748A (zh) 用於治療贅瘤形成之治療組合及方法
JP2021522847A (ja) Ｏｘ４０に対する完全ヒト抗体、それを調製する方法、およびその使用
KR20180100412A (ko) 면역강화제에 의해 증진되는 초항원 매개된 암 면역요법
KR20200124701A (ko) 항―ｐｄ－１ 항체 및 그의 용도
WO2018047917A1 (ja) Ｈｍｇタンパク質と抗ｃｄ４抗体又は免疫チェックポイント制御剤との組み合わせによる相乗的抗腫瘍効果
CN111973739B (zh) 抗pd-l1单克隆抗体治疗癌症的用途
CN114364400A (zh) 使用pd-1轴抑制剂及抗骨膜蛋白抗体治疗癌症的方法
CN116710486A (zh) 用于治疗癌症的多特异性抗体
CN113811329A (zh) 抗pd-1抗体和其用途
CN109195626B (zh) 结合死亡受体4和死亡受体5的抗体
TWI887285B (zh) 抗ｇａｒｐ抗體與免疫調節劑之組合及其用途
EP4402173A1 (en) Multispecific antibodies for use in treating diseases
CN117355331A (zh) 抗Siglec组合物及其用途
US20250195645A1 (en) Combination of multispecific molecule and immune checkpoint inhibitor
CN121668303A (zh) 抗pd-1抗体在联合用药中的应用
EA045980B1 (ru) Антитела против рецептора полиовируса (pvr) и их применение

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20200825

A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20200918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230522

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230526

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230613

R150 Certificate of patent or registration of utility model

Ref document number: 7302793

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150